Ask AI
ProCE Banner Activity

Smoldering and Spiking: Mapping MS and Modern DMTs

Podcast Episodes

This episode delivers a practical update on multiple sclerosis (MS) treatment, explaining MS as a spectrum of relapsing attacks and smoldering, progression-related neurodegeneration (PIRA/RAW) and what that means for slowing disability. It reviews today’s multiple sclerosis disease-modifying therapies, especially high-efficacy anti-CD20 monoclonals, as well as emerging trial designs, such as OCTOPUS, aimed at improving options for progressive MS and future CNS repair.

Released: March 13, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for healthcare professionals in neurology who provide care for patients with MS, including physicians, nurse practitioners, physician associates, and pharmacists. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the immunopathogenic mechanisms and biologic basis of MS in the context of available treatment options

  • Evaluate clinical trial data on approved and emerging DMTs for relapsing MS

  • Apply efficacy, safety, and disease activity metrics to tailor treatment selection and monitoring plans for relapsing MS

  • Incorporate evidence-based communication techniques and multidisciplinary care approaches to support shared decision-making, improve adherence, and optimize long-term outcomes in MS management

Disclosure

Primary Author

Patricia K. Coyle, MD, FAAN, FANA: consultant/advisor/speaker: Accordant, Amgen, GSK, Horizon Therapeutics, Novartis, Sanofi Genzyme; researcher: CorEvitas, Genentech/Roche, Sanofi Genzyme.